McKesson to Spin Off Medical-Surgical Company

Dow Jones

May 09, 2025

By Katherine Hamilton

McKesson plans to separate its medical-surgical business into a new company.

The pharmaceutical distributor on Thursday said the new company would be a differentiated medical surgical supply and solutions business.

McKesson expects the spinoff will improve operational focus and improve value for shareholders of both McKesson and the new company. The company focused on expanding its oncology and biopharmaceutical segments during the first quarter, it said.

The medical-surgical solutions segment brought in $2.85 billion of revenue in the fiscal fourth quarter, up 1% from the year before.

"Disciplined capital deployment and portfolio management are hallmarks of our strategy," Chief Executive Officer Brian Tyler said. "We believe that the separation will deliver sustainable long-term growth for both companies."

McKesson posted a 19% increase in revenue to $90.8 billion in the fiscal fourth quarter. It had a profit of $1.26 billion, or $10.01 a share, in the quarter ended March 31, compared with $791 million, or $6.02 a share, the year before.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 08, 2025 17:29 ET (21:29 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2534616012"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534616012\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2534616012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-09 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534616012","market":"sg","top_or_hot":-1,"title":"McKesson to Spin Off Medical-Surgical Company","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  McKesson plans to separate its medical-surgical business into a new company. \n</p>\n<p>\n  The pharmaceutical distributor on Thursday said the new company would be a differentiated medical surgical supply and solutions business. \n</p>\n<p>\n  McKesson expects the spinoff will improve operational focus and improve value for shareholders of both McKesson and the new company. The company focused on expanding its oncology and biopharmaceutical segments during the first quarter, it said. \n</p>\n<p>\n  The medical-surgical solutions segment brought in $2.85 billion of revenue in the fiscal fourth quarter, up 1% from the year before. \n</p>\n<p>\n  \"Disciplined capital deployment and portfolio management are hallmarks of our strategy,\" Chief Executive Officer Brian Tyler said. \"We believe that the separation will deliver sustainable long-term growth for both companies.\" \n</p>\n<p>\n  McKesson posted a 19% increase in revenue to $90.8 billion in the fiscal fourth quarter. It had a profit of $1.26 billion, or $10.01 a share, in the quarter ended March 31, compared with $791 million, or $6.02 a share, the year before. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2025 17:29 ET (21:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>McKesson to Spin Off Medical-Surgical Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMcKesson to Spin Off Medical-Surgical Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-09 05:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  McKesson plans to separate its medical-surgical business into a new company. \n</p>\n<p>\n  The pharmaceutical distributor on Thursday said the new company would be a differentiated medical surgical supply and solutions business. \n</p>\n<p>\n  McKesson expects the spinoff will improve operational focus and improve value for shareholders of both McKesson and the new company. The company focused on expanding its oncology and biopharmaceutical segments during the first quarter, it said. \n</p>\n<p>\n  The medical-surgical solutions segment brought in $2.85 billion of revenue in the fiscal fourth quarter, up 1% from the year before. \n</p>\n<p>\n  \"Disciplined capital deployment and portfolio management are hallmarks of our strategy,\" Chief Executive Officer Brian Tyler said. \"We believe that the separation will deliver sustainable long-term growth for both companies.\" \n</p>\n<p>\n  McKesson posted a 19% increase in revenue to $90.8 billion in the fiscal fourth quarter. It had a profit of $1.26 billion, or $10.01 a share, in the quarter ended March 31, compared with $791 million, or $6.02 a share, the year before. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2025 17:29 ET (21:29 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1814569148.SGD","symbol_name":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2534616012","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534616012","pubTimestamp":1746739740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"McKesson plans to separate its medical-surgical business into a new company.The pharmaceutical distributor on Thursday said the new company would be a differentiated medical surgical supply and solutions business.McKesson expects the spinoff will improve operational focus and improve value for shareholders of both McKesson and the new company. The company focused on expanding its oncology and biopharmaceutical segments during the first quarter, it said.The medical-surgical solutions segment brought in $2.85 billion of revenue in the fiscal fourth quarter, up 1% from the year before.\"Disciplined capital deployment and portfolio management are hallmarks of our strategy,\" Chief Executive Officer Brian Tyler said. \"We believe that the separation will deliver sustainable long-term growth for both companies.\". McKesson posted a 19% increase in revenue to $90.8 billion in the fiscal fourth quarter. It had a profit of $1.26 billion, or $10.01 a share, in the quarter ended March 31, compared wi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","MCK":"麦克森药物批发","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","BK4585":"ETF&股票定投概念","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","BK4175":"保健护理产品经销商","LU0861579265.USD":"联博低波幅策略股票基金A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","BK4588":"碎股","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC"},"translate_title":"麦克森将分拆医疗外科公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1},"content_text":"By Katherine Hamilton \n\n\n  McKesson plans to separate its medical-surgical business into a new company. \n\n\n  The pharmaceutical distributor on Thursday said the new company would be a differentiated medical surgical supply and solutions business. \n\n\n  McKesson expects the spinoff will improve operational focus and improve value for shareholders of both McKesson and the new company. The company focused on expanding its oncology and biopharmaceutical segments during the first quarter, it said. \n\n\n  The medical-surgical solutions segment brought in $2.85 billion of revenue in the fiscal fourth quarter, up 1% from the year before. \n\n\n  \"Disciplined capital deployment and portfolio management are hallmarks of our strategy,\" Chief Executive Officer Brian Tyler said. \"We believe that the separation will deliver sustainable long-term growth for both companies.\" \n\n\n  McKesson posted a 19% increase in revenue to $90.8 billion in the fiscal fourth quarter. It had a profit of $1.26 billion, or $10.01 a share, in the quarter ended March 31, compared with $791 million, or $6.02 a share, the year before. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2025 17:29 ET (21:29 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}